FINNENCE ▪ THE WIRE FILE
THE WIRE · № 67271
News■ Unclear/unknown
Aesthetic Management Partners Introduces Cellenis® Exo-ME™, Bringing Autologous Extracellular Vesicle Technology to the Skin Booster Market
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-06 13:30 UTC
LAST UPDATE2026-10-06 13:30 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Private aesthetics product launch; no public-company or pricing detail.
Aesthetic product PR, no investable angle
CATALYST TO WATCH
Regulatory or sales data
MAIN RISK
Unproven commercial traction
FULL DISPATCH
New technology expands the Cellenis® PRP portfolio, building on a globally utilized platform to deliver a personalized approach to skin quality MEMPHIS, Tenn., Oct. 6, 2026 /PRNewswire/ -- Aesthetic Management Partners today announced the introduction of Cellenis® Exo-ME™, an autologous,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
TRex Bio sets terms for Nasdaq IPO of up to $128.7 million, with Lilly eyeing stake2026-10-06 13:35 UTC
TRex Bio sets terms for Nasdaq IPO of up to $128.7 million, with Lilly eyeing stake2026-10-06 13:35 UTC
→CORRELATIONshares Healthcare
Washington State Expands No-Cost Support for Rural Family Caregivers Through Trualta2026-10-06 14:00 UTC
Washington State Expands No-Cost Support for Rural Family Caregivers Through Trualta2026-10-06 14:00 UTC
←CORRELATIONshares Healthcare
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms2026-10-06 08:21 UTC
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms2026-10-06 08:21 UTC
←CORRELATIONshares Healthcare
Bausch Health to Announce Third Quarter 2026 Results on October 28, 20262026-10-06 11:00 UTC
Bausch Health to Announce Third Quarter 2026 Results on October 28, 20262026-10-06 11:00 UTC
←CORRELATIONshares Healthcare
TranspireBio Announces Successful Completion of a Pivotal Phase 1 Study with its Proprietary Springboard™ Soft Mist Inhaler Platform2026-10-06 11:15 UTC
TranspireBio Announces Successful Completion of a Pivotal Phase 1 Study with its Proprietary Springboard™ Soft Mist Inhaler Platform2026-10-06 11:15 UTC
←CORRELATIONshares Healthcare
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results2026-10-06 11:30 UTC
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results2026-10-06 11:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.